Satoru Imura

Satoru Imura

Auto-generated profile, based on publicly available information

Satoru Imura

Department of Surgery, Tokushima University, Tokushima, Japan

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2014 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Open access
PDF file
TUTakahiro Uenishi
Takahiro Uenishi
SAShunichi Ariizumi
Shunichi Ariizumi
TATaku Aoki
Taku Aoki
TETomoki Ebata
Tomoki Ebata
MOMasayuki Ohtsuka
Masayuki Ohtsuka
TTTadahiro Takada
Tadahiro Takada
Background Recently, the Liver Cancer Study Group of Japan (LCSGJ) staging system for intrahepatic cholangiocarcinoma (ICC) was followed by a proposal of the American Committee on Cancer (AJCC)/International Union Against Cancer (UICC) system. The present study aimed to assess the accuracy of both systems to predict survival after curative resection for mass‐forming ICC and to establish a new staging system based on survival analysis results. The present study was conducted as a project study of the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery. Methods Clinical data from 233 patients who underwent curative resection for mass‐forming ICC were retrospectively reviewed. Survival analysis was performed to identify predictors of postoperative outcomes, and a new staging system was established. The survival stratification of our proposed system was compared with two previous staging systems. Results A N0M0 cohort analysis demonstrated that tumor size, tumor number, and vascular invasion were independently associated with survival after curative resection for mass‐forming ICC, whereas serosal and periductal invasion were not. Of patients with nodal metastases, patients with T4 tumor had significantly lower overall survival rate than patients with T1, T2, or T3 tumor. Thus, we proposed a new staging system as follows: serosal invasion was excluded from the LCSGJ T categories, and patients with nodal metastases were divided into stage IVA or IVB according to T classification. The new system better stratified survival after curative resection for mass‐forming ICC than the two previous systems. Conclusions The AJCC/UICC staging system failed to stratify the Japanese patients with mass‐forming ICC. The new staging system provided better survival prediction in the patients who underwent curative resection for mass‐forming ICC, although further studies are necessary to evaluate the impact of tumor size on survival.

29 March 2021 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
SYShinichiro Yamada
Shinichiro Yamada
MSMitsuo Shimada
Mitsuo Shimada
YMYuji Morine
Yuji Morine
SISatoru Imura
Satoru Imura
TITetsuya Ikemoto
Tetsuya Ikemoto
MNMasaaki Nishi
Masaaki Nishi
Background: Frailty is an important consideration for older patients undergoing surgery. We aimed to investigate whether frailty could be a prognostic factor in patients with pancreatic ductal adenocarcinoma who underwent pancreatic resection. Methods: One hundred and twenty patients who underwent pancreatic resection for pancreatic ductal adenocarcinoma were enrolled. Frailty was defined as a clinical frailty scale score ≥4. Patients were divided into frailty (n = 29) and non-frailty (n=91) groups, and clinicopathological factors were compared between the two groups. Results: The frailty group showed an older age, lower serum albumin concentration, lower prognostic nutritional index, larger tumor diameter, and higher rate of lymph node metastasis than the non-frailty group (p < 0.05). Neutrophil–lymphocyte ratio and modified Glasgow prognostic score tended to be higher in the frailty group. Cancer-specific and disease-free survival rates were significantly poor in the frailty group (p < 0.05). With a multivariate analysis, frailty was an independent prognostic factor of cancer-specific survival. Conclusions: Frailty can predict the prognosis of patients with pancreatic ductal adenocarcinoma who undergo pancreatic resection.

14 June 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
RFRui Feng
Rui Feng
YMYuji Morine
Yuji Morine
TITetsuya Ikemoto
Tetsuya Ikemoto
SISatoru Imura
Satoru Imura
SIShuichi Iwahashi
Shuichi Iwahashi
MSMitsuo Shimada
Mitsuo Shimada
Cancer‐associated fibroblasts (CAF), derived from stroma of cancer tissues, interact with cancer cells and play an important role in cancer initiation, growth, and metastasis. Nab‐paclitaxel (nab‐PTX) is a 130 nm albumin‐binding paclitaxel and recommended for many types of cancer chemotherapy. The nab‐PTX stromal‐disrupting effect during pancreatic cancer treatment has been reported. The aim of the present study was to determine the role of nab‐PTX in cancer cells and CAF interaction. Cancer cells (MIA PaCa‐2 and Panc‐1) were cocultured with CAF or treated with CAF conditioned medium, after which their migration and invasion ability, epithelial‐mesenchymal transition (EMT)‐related marker expression and C‐X‐C motif chemokine 10 (CXCL10) expression and secretion were detected. Nab‐PTX treatment was carried out during the coculture system or during preparation of CAF conditioned medium. Then cancer cell migration and invasion ability, EMT‐related marker expression, CXCL10 expression and secretion, and interleukin‐6 (IL‐6) expression and secretion by CAF were checked After coculture with CAF, migration and invasion ability of cancer cells increased. CAF also downregulated E‐cadherin and upregulated N‐cadherin and vimentin expression in cancer cells. During coculture or stimulation with cancer cell‐cultured medium, CAF significantly increased IL‐6 expression and secretion. However, nab‐PTX in the coculture system canceled CAF‐induced migration and invasion promotion and EMT‐related gene changes. Moreover, nab‐PTX increased CXCL10 expression of cancer cells which blocked CAF IL‐6 expression and secretion. Nab‐PTX treatment could increase CXCL10 expression of cancer cells which blocks CAF cancer cell migration and invasion‐promoting effect by inhibiting IL‐6 expression.

16 February 2021 in Oncotarget
Verified
Journal Article
Open access
PDF file
KTKazunori Tokuda
Kazunori Tokuda
YMYuji Morine
Yuji Morine
KMKatsuki Miyazaki
Katsuki Miyazaki
SYShinichiro Yamada
Shinichiro Yamada
YSYu Saito
Yu Saito
MSMitsuo Shimada
Mitsuo Shimada
Https://doi.org/10.18632/oncotarget.27881 Kazunori Tokuda, Yuji Morine, Katsuki Miyazaki, Shinichiro Yamada, Yu Saito, Masaaki Nishi, Takuya Tokunaga, Tetsuya Ikemoto, Satoru Imura, Mitsuo Shimada

1 January 2013 in The Journal of Medical Investigation
Verified
Journal Article
Open access
PDF file
YSYu Saito
Yu Saito
MSMitsuo Shimada
Mitsuo Shimada
TUTohru Utsunomiya
Tohru Utsunomiya
YMYuji Morine
Yuji Morine
SISatoru Imura
Satoru Imura
HIHiroki Ishibashi
Hiroki Ishibashi
A patient with hepatic epithelioid angiomyolipoma (Epi-AML) with arterioportal venous shunting, who was successfully treated by a laparoscopic left lateral sectionectomy, is presented herein. AML is an uncommon benign neoplasm of the liver. Tumors composed predominantly of epithelioid cells have been subcategorized into Epi-AML, and the treatment strategy for Epi-AML is currently undetermined. There are no reports describing Epi-AML with arterioportal venous shunting to date. An arterioportal venous shunting of the liver tumor was suggested to be one of the malignant signs of the liver tumor. It would be important to differentiate Epi-AML with arterioportal venous shunting from hepatocellular carcinoma and hypervascular metastatic tumors. Minimally invasive resection, such as laparoscopic hepatectomy, for patients having Epi-AML with arterioportal venous shunting may be recommended. J. Med. Invest. 60: 262-266, August, 2013

1 June 1992 in Rheumatology
Verified
Journal Article
Closed access
PDF file
Shunichi ShiozawaShunichi Shiozawa
Shunichi Shiozawa
KSK. Shiozawa
K. Shiozawa
MKMasaki Kita
Masaki Kita
TKT. Kishida
T. Kishida
TFTakeshi Fujita
Takeshi Fujita
SIS. Imura
S. Imura
A 12-week, double-blind controlled study comparing low dose α-interferon (5×105 iu, twice a week) and placebo was carried out to determine whether this drug has an immunomodulatory effect in rheumatoid arthritis. There were statistically significant improvements in the patients' joint score, C-reactive protein value and platelet count, without any side effects. Interferon-a caused an increase of serum calcium and a decrease of alkaline phosphatase. Thus, α-interferon requires further investigation as a possible additional useful treatment for rheumatoid arthritis